Promoting Antibacterial Drug Development: Select Policies and Challenges.

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Infectious Disease Research

Background:

• The antibacterial drug development pipeline is insufficient to meet the growing demand for treatments against rising antimicrobial resistance.
• Existing efforts to incentivize antibacterial drug development have proven inadequate.
• There is a critical need for targeted incentives that promote both the creation of new antibacterial drugs and their responsible use.

Purpose of the Study:

• To analyze the impact of two distinct incentive mechanisms on the financial returns of antibacterial drug companies.
• To evaluate a 5-year delay in generic competition and a US$50 million prize for Food and Drug Administration approval as potential incentives.
• To inform policy development for fostering innovation in antibacterial drug development.

Main Methods:

• Utilized a decision-tree framework developed for the US Department of Health and Human Services.
• Modeled the drug company decision-making process as a revenue maximization problem under conditions of uncertainty.
• Applied economic principles to assess the efficacy of different incentive structures.

Main Results:

• Incentive effectiveness is contingent upon the specific indications a new antibacterial drug targets and its stage of development.
• A one-size-fits-all approach to incentives is suboptimal for maximizing societal benefit.
• The analyzed incentives demonstrate a tendency to under-incentivize early-stage development while over-incentivizing late-stage development.

Conclusions:

• Optimal policies must balance societal benefits (e.g., reduced public health burden from infectious diseases) with social costs.
• Incentive structures should be tailored to address the specific challenges of different development stages.
• Current incentive models require refinement to effectively stimulate the development of novel antibacterial agents and ensure prudent use, thereby combating antimicrobial resistance.